Combination Therapy with Dipyridamole and Clopidogrel for Secondary Stroke Prevention in Aspirin-Intolerant Patients After Myocardial Infarction: Results of a Nationwide Case-Control Study.
Aged
Case-Control Studies
Cerebral Hemorrhage
/ chemically induced
Clopidogrel
/ administration & dosage
Dipyridamole
/ administration & dosage
Disease-Free Survival
Drug Therapy, Combination
Female
Gastrointestinal Hemorrhage
/ chemically induced
Humans
Kaplan-Meier Estimate
Male
Myocardial Infarction
/ drug therapy
Proportional Hazards Models
Secondary Prevention
/ methods
Stroke
/ mortality
Survival Rate
Journal
CNS drugs
ISSN: 1179-1934
Titre abrégé: CNS Drugs
Pays: New Zealand
ID NLM: 9431220
Informations de publication
Date de publication:
02 2019
02 2019
Historique:
pubmed:
17
1
2019
medline:
19
5
2020
entrez:
17
1
2019
Statut:
ppublish
Résumé
Combination therapy with dipyridamole and clopidogrel in stroke prevention and long-term outcomes in aspirin-intolerant patients with acute myocardial infarction (AMI) and previous stroke are unknown. This nationwide study analyzed the impact of dipyridamole and clopidogrel on secondary stroke prevention and long-term outcomes in aspirin-intolerant stroke patients after AMI. This was a nationwide, case-control study involving 186,112 first AMI patients, 78,607 of whom had a previous history of stroke. In the final analysis, we included 4637 patients taking clopidogrel alone and 208 patients using a combination of clopidogrel and dipyridamole. The 12-year survival rate was not different between clopidogrel and clopidogrel-dipyridamole groups (log-rank p = 0.6247). Furthermore, there were no differences in event-free survival after stroke (log-rank p = 0.6842), gastrointestinal (GI) bleeding (log-rank p = 0.9539), or intracerebral hemorrhage (ICH; log-rank p = 0.6191) between the two groups. Dipyridamole did not contribute significantly to AMI survival (hazard ratio 0.98, 95% confidence interval 0.84-1.15), and did not show benefits in any of the subgroups regardless of sex, age (younger or older than 75 years), comorbidities, percutaneous coronary intervention, or medications. No differences were observed in the 12-year survival rate between clopidogrel and clopidogrel-dipyridamole groups. The two groups had balanced event-free survival in recurrent stroke, ICH, GI bleeding, and myocardial infarction.
Sections du résumé
BACKGROUND AND PURPOSE
Combination therapy with dipyridamole and clopidogrel in stroke prevention and long-term outcomes in aspirin-intolerant patients with acute myocardial infarction (AMI) and previous stroke are unknown. This nationwide study analyzed the impact of dipyridamole and clopidogrel on secondary stroke prevention and long-term outcomes in aspirin-intolerant stroke patients after AMI.
METHODS
This was a nationwide, case-control study involving 186,112 first AMI patients, 78,607 of whom had a previous history of stroke. In the final analysis, we included 4637 patients taking clopidogrel alone and 208 patients using a combination of clopidogrel and dipyridamole.
RESULTS
The 12-year survival rate was not different between clopidogrel and clopidogrel-dipyridamole groups (log-rank p = 0.6247). Furthermore, there were no differences in event-free survival after stroke (log-rank p = 0.6842), gastrointestinal (GI) bleeding (log-rank p = 0.9539), or intracerebral hemorrhage (ICH; log-rank p = 0.6191) between the two groups. Dipyridamole did not contribute significantly to AMI survival (hazard ratio 0.98, 95% confidence interval 0.84-1.15), and did not show benefits in any of the subgroups regardless of sex, age (younger or older than 75 years), comorbidities, percutaneous coronary intervention, or medications.
CONCLUSION
No differences were observed in the 12-year survival rate between clopidogrel and clopidogrel-dipyridamole groups. The two groups had balanced event-free survival in recurrent stroke, ICH, GI bleeding, and myocardial infarction.
Identifiants
pubmed: 30649687
doi: 10.1007/s40263-018-0591-8
pii: 10.1007/s40263-018-0591-8
pmc: PMC6373395
doi:
Substances chimiques
Dipyridamole
64ALC7F90C
Clopidogrel
A74586SNO7
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
175-185Références
Curr Pharm Des. 2016;22(29):4617-4626
pubmed: 27291399
Int J Cardiol. 2013 May 25;165(3):444-7
pubmed: 21968077
J Neurol Sci. 1996 Nov;143(1-2):1-13
pubmed: 8981292
Cardiovasc Diabetol. 2017 Jul 11;16(1):89
pubmed: 28697774
Int J Cardiol. 2015 Dec 15;201:96-101
pubmed: 26292275
PLoS One. 2015 Aug 14;10(8):e0135692
pubmed: 26274912
Lancet. 1967 Sep 2;2(7514):495-7
pubmed: 4166411
Health Technol Assess. 2004 Oct;8(38):iii-iv, 1-196
pubmed: 15461876
Clin Cardiol. 2000 Nov;23 Suppl 6:VI-18-22
pubmed: 11129682
MMWR Morb Mortal Wkly Rep. 2015 Jul 17;64(27):733-7
pubmed: 26182190
Medicine (Baltimore). 2016 Feb;95(5):e2678
pubmed: 26844504
J Neurol Sci. 2013 Sep 15;332(1-2):92-6
pubmed: 23871093
Int J Chron Obstruct Pulmon Dis. 2015 Jul 21;10:1409-16
pubmed: 26229460
J Natl Med Assoc. 2006 May;98(5):711-21
pubmed: 16749646
Br J Exp Pathol. 1977 Jun;58(3):268-72
pubmed: 871376
Eur Heart J. 2018 Jan 7;39(2):119-177
pubmed: 28886621
Medicine (Baltimore). 2016 Feb;95(6):e2742
pubmed: 26871819
J Clin Invest. 1968 Sep;47(9):2169-80
pubmed: 5675432
J Neurol Neurosurg Psychiatry. 2009 Sep;80(9):1006-11
pubmed: 19443470
Eur Heart J. 2016 Jan 14;37(3):267-315
pubmed: 26320110
Lancet. 1996 Nov 16;348(9038):1329-39
pubmed: 8918275
Stroke. 2014 Jul;45(7):2160-236
pubmed: 24788967
J Am Coll Cardiol. 2013 Jan 29;61(4):e78-e140
pubmed: 23256914
Am Fam Physician. 2017 Oct 1;96(7):436-440
pubmed: 29094912
Ned Tijdschr Geneeskd. 2013;157(25):A5836
pubmed: 23777963
Stroke. 2005 Jan;36(1):162-8
pubmed: 15569877
BMC Neurol. 2015 Nov 02;15:225
pubmed: 26525411
Presse Med. 2016 Dec;45(12 Pt 2):e457-e471
pubmed: 27816341
Handb Exp Pharmacol. 2012;(210):547-63
pubmed: 22918746
Cleve Clin J Med. 2013 Dec;80(12):787-95
pubmed: 24307163
Herz. 2014 Nov;39(7):798-802
pubmed: 25361793
ACP J Club. 2006 Nov-Dec;145(3):57
pubmed: 17080969
Circulation. 2014 Dec 23;130(25):e344-426
pubmed: 25249585
Anadolu Kardiyol Derg. 2006 Mar;6(1):24-7
pubmed: 16524796
J Cardiovasc Pharmacol Ther. 2015 Mar;20(2):144-56
pubmed: 25079473
Lancet. 2006 May 20;367(9523):1665-73
pubmed: 16714187
J Epidemiol. 2014;24(6):500-7
pubmed: 25174915
Int J Stroke. 2018 Jun;13(4):420-443
pubmed: 29171361
Lancet Neurol. 2008 Oct;7(10):875-84
pubmed: 18757238
Eur Heart J. 2013 Aug;34(31):2436-43
pubmed: 23641007
Circ J. 2007 Mar;71(3):301-7
pubmed: 17322625
Eur J Neurol. 2014 Oct;21(10):1311-7
pubmed: 25040015
Eur Heart J. 2013 Aug;34(31):2444-52
pubmed: 23625211
JAMA. 2016 Jul 5;316(1):70-8
pubmed: 27348249
N Engl J Med. 2008 Sep 18;359(12):1238-51
pubmed: 18753638